DuChemBio Q1 2026: Sales KRW 9.7bn, Operating Profit KRW 1.26bn (QoQ +14.7%, +87.5%)

Consolidated Q1 2026: Sales KRW 9,704mn (QoQ +14.7%), Operating profit KRW 1,256mn (+87.5%), Net income KRW 872mn
Credit rating upgraded to BBB+ (from BBB in 2025, Seoul Credit Rating)
Market leadership: FDG 58.2%, FP-CIT 52.0%, Amyloid PET 94.8% share (2024)
New product approvals: ProstaSeek (prostate cancer) and FES (breast cancer) received KFDA approval; supply to start in H1 2026
Overseas expansion: FP-CIT license agreement with Taiwan, extended to 6 Southeast Asian countries
R&D investment increased to 1.73% of sales (vs 0.06% in 2025); AI diagnostic platform joint development initiated